重度特发性膜性肾病患者B细胞与T细胞亚群可能预测利妥昔单抗早期应答
该研究比较了25例重度特发性膜性肾病患者与27例年龄匹配健康人的33种淋巴细胞亚群和27种细胞因子/趋化因子,并观察16例接受利妥昔单抗联合支持治疗与9例仅支持治疗患者的变化。结果显示患者基线调节性T细胞降低、NK细胞及亚群异常;利妥昔单抗应答者基线Treg比例显著低于无应答者且第8天显著升高,提示Treg评估可能有助于预测早期应答。
要点
- 重度特发性膜性肾病患者基线调节性T细胞比例显著降低,NK细胞比例显著降低且CD56brightCD16-/lo亚群增加。
- 利妥昔单抗治疗后6个月B细胞恢复仍不完全,B细胞亚群持续改变;Treg和NK细胞显著增加,CD56brightCD16-/lo亚群和TNF-α水平显著降低。
- 利妥昔单抗临床应答者基线Treg比例显著低于无应答者,第8天Treg比例显著升高,无应答者及仅支持治疗者Treg无变化。
核心结论
- 评估调节性T细胞可能有助于预测重度特发性膜性肾病患者对利妥昔单抗的早期应答。
研究设计与样本
- 研究比较25例重度特发性膜性肾病患者与27例年龄匹配健康人的33种淋巴细胞亚群和27种细胞因子/趋化因子。
- 进一步观察16例接受利妥昔单抗联合支持治疗的患者(第8天、3个月和6个月)与9例仅接受支持治疗的患者。
主要发现
- 基线时患者幼稚B细胞百分比显著增加,转换型和非转换型记忆B细胞百分比显著降低。
- 基线时NK细胞百分比显著降低,CD56brightCD16-/lo NK亚群增加,调节性T细胞百分比显著降低,血浆TNF-α、IL-5和IL-2RA浓度升高。
- 利妥昔单抗治疗后6个月B细胞恢复仍不完全,B细胞亚群持续改变,Treg细胞和NK细胞显著增加,CD56brightCD16-/lo NK亚群和TNF-α水平显著降低。
- 利妥昔单抗临床应答者基线Treg百分比显著低于无应答者,第8天Treg百分比显著升高;无应答者和仅支持治疗者Treg无变化。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary membranous nephropathy (PMN) is characterized by antibodies to the podocyte, but little is known about B- and T-cell populations and their response to rituximab is controversial. To help resolve this we compared 33 lymphocyte subpopulations and 27 cytokines/chemokines in 25 patients with severe PMN and 27 age-matched healthy individuals. At baseline, patients had a significantly increased percentage of naive B-cells with significantly decreased switched and non-switched memory B-cells. There was a significantly decreased percentage of natural killer (NK) cells with an increase in the CD56brightCD16-/lo NK subset. There were a significantly decreased percentage of regulatory T cells, together with an increased plasma concentration of TNF-alpha, IL-5 and IL-2RA. We then investigated 16 patients at eight days and three and six months after treatment with rituximab added to supportive therapy compared to nine patients with supportive therapy alone. After rituximab, B-cell recovery was still incomplete at six months, with persistent alterations of B-cell subsets, a significant increase of both T-regulatory (Treg) cells and NK cells, and a significant decrease of both the CD56brightCD16-/lo NK subset and TNF-alpha levels. The patients who clinically responded to rituximab had a significantly lower percentage of Tregs at baseline compared to non-responders and a significantly increased percentage at day eight. Tregs remained unchanged in non-responders and in patients treated with supportive therapy alone. Thus, evaluation of Tregs might be useful for predicting early response to rituximab.
引用
- Rosenzwajg M, Languille E, Debiec H, et al. B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab. Kidney Int. 2017. PMID: 28318628. doi:10.1016/j.kint.2017.01.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。